Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
RegulatorypositiveZeydovioPositive
AI Analysis
Summary
Zealand Pharma received a positive CHMP opinion for Zeydovio (glepaglutide) for the treatment of short bowel syndrome, representing a regulatory milestone toward European approval.
Outcome Details
positive CHMP opinion received
Importance:8/10
Sentiment:
0.85
regulatory approvalCHMP opinionEuropeglepaglutideshort bowel syndrome
Related Companies
Read the original article
Published by yahoo_finance on September 18, 2026 10:10 AM